Výsledky vyhledávání - "David Millson"

Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study

Autor: Shigeru Iwata, Shingo Nakayamada, David Millson, Yoshiya Tanaka

Publikováno v: Rheumatology. 60:2884-2895

Objective The primary objectives of two phase II studies of fostamatinib were to evaluate efficacy (OSKIRA-Asia-1: NCT01569074) and long-term safety/tolerability (OSKIRA-Asia-1X: NCT01640054) in patients from Asia with active RA despite MTX treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a539e7c9d293a781593f99682501301
https://doi.org/10.1093/rheumatology/keaa732

Zobrazit plný text záznamu

As clean as they look? Food hygiene inspection scores, microbiological contamination, and foodborne illness

Autor: Darren Holland, Laura Thomson, Shamim Rahman, Janet Fleetwood, David Millson, Guy M. Poppy

Publikováno v: Food Control. 96:76-86

This work describes the relationship between compliance with food hygiene law as reflected in food hygiene scores; measures of microbiological contamination of food samples taken from consumer-facing food businesses in England, Northern Ireland and W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23a0be086a151752e2ed2cd1afd5a8a
https://doi.org/10.1016/j.foodcont.2018.08.034

Zobrazit plný text záznamu

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

Autor: Stuart Oliver, David Millson, Paul D. Martin, Philip T. Leese, Michael Gillen, Dominic Surry, Clive Brealey, David Lau, David J. Sweeny

Publikováno v: Clinical Pharmacology in Drug Development. 5:170-179

Fostamatinib is a prodrug that undergoes gastrointestinal tract dephosphorylation to form the active metabolite, R406. Here we report its cytochrome P450-inducing potential. In vitro, R406 3 and 10 μM induced CYP2C8 to levels representing 53% and 75

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::351e92f4de8689a4ec9b21b7dd42b8ef
https://doi.org/10.1002/cpdd.243

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies

Autor: Robert Elsby, Michael Gillen, Muhammad Baluom, David Lau, Tim Mant, Paul D. Martin, David Millson, Stuart Oliver, Clive Brealey

Publikováno v: Clinical Therapeutics. 37:2811-2822

Purpose Fostamatinib, a spleen tyrosine kinase inhibitor and prodrug of the active metabolite R406, is being developed as an anti-inflammatory drug for several indications for which polypharmacy is likely. Digoxin, indicated for congestive cardiac fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39ab6837328faad573fbe22eed9c317
https://doi.org/10.1016/j.clinthera.2015.09.018

Zobrazit plný text záznamu

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Autor: Sally Hollis, David Millson, Arthur Kavanaugh, Krystyna Rosiak-Jedrychowicz, Michael E. Weinblatt, Désirée van der Heijde, Meilien Ho, Mark C. Genovese, Gustavo Leon, Millie Wang

Publikováno v: Arthritis and Rheumatology, 66(12), 3255-3264

Objective This phase III, 52-week study compared fostamatinib with placebo (for 24 weeks) in patients with active rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) therapy. Methods Patients taking MTX were randomized (1:1:1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52e76ef9310056edb480994978480f42
https://doi.org/10.1002/art.38851

Zobrazit plný text záznamu

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

Autor: Paul D. Martin, Clive Brealey, Tim Mant, David J. Sweeny, Kelli Craven, Elliott B. Grossbard, Stuart Oliver, David Millson, Muhammad Baluom, David Lau, Michael Gillen

Publikováno v: Drugs in R&D

Background Fostamatinib (R788) is a spleen tyrosine kinase (SYK) inhibitor. The active metabolite of fostamatinib, R406, is primarily metabolized by CYP3A4. Objectives The aim of this study was to characterize hepatic microsomal metabolism of R406 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500247c9fefb954306521b3088336334
https://pubmed.ncbi.nlm.nih.gov/26739683

Zobrazit plný text záznamu

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

Autor: Paul, Martin, Michael, Gillen, David, Millson, Stuart, Oliver, Clive, Brealey, Dominic, Surry, David, Sweeny, David, Lau, Philip, Leese

Publikováno v: Clinical pharmacology in drug development. 5(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8b5c43b77f803eb2827e4ce9555d6f33
https://pubmed.ncbi.nlm.nih.gov/27163495

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání